London-listed rare disease specialist Shire (LSE: SHP) has released more data on its chronic hypoparathyroidism candidate, recombinant human parathyroid hormone (rhPTH[1-84]).
The company presented clinical and real-world data designed to provide “new insights into the burden of the disease.”
One study looked at renal function in patients treated with rhPTH[1-84], compared to an historical control cohort over three years. Another five-year trial provided long-term safety and efficacy data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze